SIGA Technologies

Historical price data

SIGA Technologies is a biopharmaceutical company with a specialized mission to address health security threats, particularly biological, chemical, radiological, and nuclear (CBRN) agents. Its primary achievement is the development and regulatory approval of TPOXX, the first and only FDA-approved drug for smallpox, supported by substantial procurement contracts from the U.S. government's Strategic National Stockpile. The company's strategic direction involves leveraging its antiviral expertise to expand its pipeline for other high-consequence pathogens and to pursue international sales of its approved product. Its financial position is strengthened by recurring government contracts, providing a stable revenue base.

Small-molecule antiviral drug discovery platform focused on inhibiting essential viral proteins, with proven application against orthopoxviruses through structure-based design.

SIGA's main competitor is Chimerix's brincidofovir, an alternative FDA-approved smallpox treatment. However, TPOXX is the market-leading and preferred therapeutic. The competitive landscape is defined by government procurement rather than traditional commercial marketing, with SIGA's first-mover advantage, proven delivery capability, and established government relationships serving as primary differentiators.